Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-03-18
2008-03-18
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S091310, C435S320100, C435S455000, C435S458000, C536S023100, C536S024500
Reexamination Certificate
active
10192980
ABSTRACT:
Described are compositions and methods relating to gene therapy, particularly as applied to hematopoietic progenitor (HP) cells, to transduced cells and methods of obtaining them, and to methods of using them to provide prolonged engraftment of modified hematopoietic cells in human subjects. The invention particularly relates to ex vivo gene therapy of HP cells for treatment or prevention of HIV infection.
REFERENCES:
patent: 5500357 (1996-03-01), Taira et al.
patent: 5525468 (1996-06-01), McSwiggen et al.
patent: 5693535 (1997-12-01), Draper et al.
patent: 5712384 (1998-01-01), Symonds et al.
patent: 5911983 (1999-06-01), Barranger et al.
patent: 6114167 (2000-09-01), Symonds et al.
patent: 6287864 (2001-09-01), Bagnis et al.
patent: 2002/0058636 (2002-05-01), Symonds et al.
patent: 2003/0082158 (2003-05-01), Symonds et al.
patent: 0321201 (1989-06-01), None
patent: 0612844 (1994-08-01), None
patent: WO 9104324 (1991-04-01), None
patent: 9217211 (1992-10-01), None
patent: WO 9400012 (1994-01-01), None
patent: WO 9416736 (1994-08-01), None
patent: WO 9504818 (1995-02-01), None
patent: WO 95/18854 (1995-08-01), None
patent: WO 96/22368 (1996-07-01), None
patent: WO 97/47770 (1997-12-01), None
patent: WO 00/34495 (2000-06-01), None
patent: 02059300 (2002-08-01), None
patent: 03006612 (2003-01-01), None
Kohn et al. 1999 A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34+ cells from the bone marrow of human immunodeficiency virus-1-infected children Blood, vol. 94 pp. 368-371.
Gervaix et al. 1997 Gene therapy targeting peripheral blood cd34+ hematopoietic stem cells of HIV-infected individuals Human Gene Therapy 8:2229-2238.
Lee et al. 2002 Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nature Biotechnology 19:500-505.
Slobod et al. 1996 Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected individuals. Blood vol. 99(9):3329-3335.
U.S. Appl. No. 08/375,291, filed Jan. 18, 1995, application with pending claims as of Jan. 10, 2002 (Exhibit 6).
Amado et al., “Effects of Megakaryocyte Growth and Development Factor on Survival and Retroviral Transduction of T Lymphoid Progenitor Cells”, Human Gene Therapy 9:173-183 (1998) (Exhibit 8).
Barinaga, Science 262:1512 (1993) (Exhibit 9).
Berzal-Herranz, A. et al. “Essential Nucleotide Sequences and Secondary Structure Elements of the Hairpin Ribozyme.” EMBO 12:2567-2574 (1993) (Exhibit 10).
Bevec, D. et al., “Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human T Cells by Retroviral-Mediated Gene Transfer of a Dominant-Negative Rev Trans-Activator.” Proc. Natl. Acad. Sci. 89:9870-9874 (1992) (Exhibit 11).
Bischofberger, N. and Wagner, R.W. “Antisense Approaches to Antiviral Agents”. Virology 3:57-66 (1992) (Exhibit 12).
Buckley, Abstract #446, [online] 2001 Retrieved from Internet: <URL:http://www4.od.nih.gov/oba/rac/hgtprep.asp> (Exhibit 13).
Cech et al., Ribozyme engineering Curr. Opin. Structural Biol. 2:605-609 (Exhibit 14).
Chen, C-J. et al., “Inhibition of HIV-1 Replication by Novel Multitarget Ribozymes”. Ann. N.Y. Acad. Sci. 660:271-273 (1992) (Exhibit 15).
Chen, C-J. et al., “Multitarget-Ribozyme directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates”. Nucleic Acids Res. 20:4581-4589 (1992) (Exhibit 16).
Chowrira, B.M. “Four Ribose 2′-Hydroxyl Groups Essential for Catalytic Function of the Hairpin Ribozyme”. J. Biol. Chem. 268:19458-19462 (1993) (Exhibit 17).
Chu, “Retrovirus-mediated gene transfer into human hematopoietic stem cells”, J. Mol. Med. 76:184-192 (1998) (Exhibit 18).
Cournoyer, D. and Caskey, C.T. “Gene Therapy of the Immune System” Annu. Rev. Immunol. 11:297-329 (1993) (Exhibit 19).
Crisell, P. et al., “Inhibition of HIV-1 Replication by Ribozymes that Show Poor Activity in vitro” Nucleic Acids Res. 21:5251-5255 (1993) (Exhibit 20).
Donahue et al., J. Vir. 62:722 (1988) (Exhibit 21).
Dropulic, B. et al., (1992) J. Virol. 66:1432-1441 (Exhibit 22).
Dropulic, B. et al., “Ribozymes: Use As Anti-HIV Therapeutic Molecules”. Antisense Res. Dev. 3:87-94 (1993) (Exhibit 23).
Gervaix, “Gene Therapy Targeting Peripheral Blood CD34+Gene Hematopoietic Stem Cells of HIV-Infected Individuals” Human Therapy 8:2229-2238 (1997) (Exhibit 24).
Goodchild et al., “Antisense Antivirals”. Antisense Res. Dev. 1:361-364 (1991) (Exhibit 25).
Goodchild et al., Enhancement of ribozyme catalytic activity, by a contigous oligodeoxynucleotide (facilitator) and by 2′-O-methylation Nucleic Acids Res. 20:4607-4612 (1992) (Exhibit 26).
Halene, “Gene Therapy Using Hematopoietic Stem Cells: Sisyphus Approaches the Crest”, Human Gene Therapy 11:1259-1267 (2000) (Exhibit 27).
Han et al. PNAS 88:4313 (1991) (Exhibit 28).
Heidenreich, O. and Eckstein F. “Hammerhead Ribozyme-Mediated Cleavage of Long Terminal Repeat RNA of Human Immundeficiency Virus Type 1”. J. Biol. Chem. 267:1904-1909 (1992) (Exhibit 29).
Homann, M. et al., “Incorporation of the Catalytic Domain of a Hammerhead Ribozyme Into Antisense RNA Enhances Its Inhibitory Effect on the Replication of Human Immunodeficiency Virus Type 1”. Nucleic Acids Res. 21:2809-2814 (1993) (Exhibit 30).
Johnston et al. “Present Status and Future Prospects for HIV Therapies”, Science 260:1286-1293 (1993) (Exhibit 31).
Joseph, S. et al. “Optimization of an Anti-Hairpin Ribozyme by in Vitro Selection” J. Biol. Chem. 268:24515-24518 (1993) (Exhibit 32).
Joseph, S. et al. “Substrate Selection Rules for the Hairpin Ribozyme Determined by in Vitro Selection, Mutation, and Analysis of Mismatched Substrates”. Genes and Development 7:130-138 (1993) (Exhibit 33).
Lever et al. J. Vir. 63:4085 (1989) (Exhibit 34).
Levy. J. “Pathogenesis of human Immunodefiency Virus Infection”. Microbiol. Rev. 57:183-289 (1993) (Exhibit 35).
Lisziewicz, J. et al., “Inhibition of Human Immunodeficiency Virus Type 1 Replication By Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy For Gene Therapy in AIDS”. Proc. Natl. Acad. Sci. 90:8000-8004 (1993) (Exhibit 36).
Liu, JM, Abstract #78, [online] 1994 Retrieved from Internet: <URL:http://www4.od.nih.gov/oba/rac/hgtprep.asp> (Exhibit 37).
Lo, K.M. et al., “Inhibition of Replication of HIV-1 by Retroviral Vectors Expressing tat-Antisense and Anti-tat Ribozyme RNA”. Virology 190:176-183 (1992) (Exhibit 38).
Lori F. et al., “Rapid Protection Against Human High HIV-1 Immunodeficiency Virus Type 1 (HIV-1) Replication Mediated by Efficiency Non-retroviral Delivery of Genes Interfering with tat and gag”. Gene Therapy 1:27-31 (1994) (Exhibit 39).
Mann et al. J. Vir. 54:401 (1985) (Exhibit 40).
Mountain, “Gene therapy: the first decade”, Tibtech vol. 18 pp. 119-128 (2000) (Exhibit 41).
Ohkawa, J. et al., “Importance of Independence in Ribozyme Reactions: Kinetic Behavior of Trimmed and of Simply Connected Multiple Ribozymes wit Potential Activity Against Human Immunodeficiency Virus”. Proc. Natl. Acad. Sci. 90:11302-11306 (1993) (Exhibit 42).
Ohkawa, J. et al., “Multiple Site-Specific Cleavage of HIV RNA by Transcribed Ribozymes from Shotgun-Type Trimming Plasmid”. Nucleic Acids Symp. Ser. 29:121-122 (1993) (Exhibit 43).
Ojwang, J.O. et al., “Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme”. Proc. Natl. Acad. Sci. 89:10802-10806 (1992) (Exhibit 44).
Olmsted et al. PNAS 86:8088 (1989) (Exhibit 45).
Ratner et al. Nature 313:277 (1985) (Exhibit 46).
Romano, “Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and
Amado Rafael G.
Fanning Gregory C.
Gerlach Wayne
MacPherson Janet L.
Sun Lun-Quan
Cooper & Dunham LLP
Johnson & Johnson Research Pty. Limited
White John P.
Zara Jane
LandOfFree
Methods for genetic modification of hematopoietic progenitor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for genetic modification of hematopoietic progenitor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for genetic modification of hematopoietic progenitor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3947302